NEW YORK, July 24, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Arena
Pharmaceuticals Inc. (NASDAQ: ARNA), StemCells Inc. (NASDAQ: STEM),
Northwest Biotherapeutics Inc. (NASDAQ: NWBO), and Acorda
Therapeutics Inc. (NASDAQ: ACOR). Free research report on PDL
BioPharma can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=PDLI On
Thursday, July 23, 2015, the NASDAQ
Composite ended at 5,146.41, down 0.49%, the Dow Jones Industrial
Average declined 0.67%, to finish the day at 17,731.92, and the
S&P 500 closed at 2,102.15, down 0.57%. The losses were broad
based as eight out of nine sectors ended the session in negative.
Register for your complimentary reports at the links given below.
PDL BioPharma Inc.'s stock finished Thursday's session 1.28%
lower at $6.18. A total of 2.02
million shares were traded, which was below its three months
average volume of 2.79 million shares. Over the last one month and
the previous three months, PDL BioPharma Inc.'s shares have
declined 7.07% and 11.08%, respectively. Additionally, the stock
has plummeted 16.21% since the beginning of 2015. The company's
shares are trading below their 50-day and 200-day moving averages
by 3.51% and 11.26%, respectively. PDL BioPharma Inc.'s stock
traded at a PE ratio of 3.24 and has a Relative Strength Index
(RSI) of 41.39. Sign up and read the free notes on PDLI at:
https://www.EquityResearchInstitute.com/reports?keyword=PDLI
On Thursday, shares in Arena Pharmaceuticals Inc. ended the
session 2.35% lower at $4.15. The
stock reported a trading volume of 1.96 million shares, below its
three months average volume of 2.77 million shares. Arena
Pharmaceuticals Inc.'s shares have lost 7.37% in the last one month
and 6.53% in the previous three months. However, the stock has
gained 19.60% on YTD basis. The company is trading 4.03% below its
50-day moving average and 4.67% below its 200-day moving average.
Moreover, shares of Arena Pharmaceuticals Inc. have an RSI of
42.44. The complimentary notes on ARNA can be downloaded in PDF
format at:
https://www.EquityResearchInstitute.com/reports?keyword=ARNA
StemCells Inc.'s stock declined 5.75%, to close the day at
$0.49. The stock recorded a trading
volume of 1.40 million shares, below its three months average
volume of 2.53 million shares. Over the last one month and over the
past three months, StemCells Inc.'s shares have plummeted 31.93%
and 40.23%, respectively. Furthermore, the stock has lost 47.86%
since the start of this year. The company's shares are trading
21.26% below their 50-day moving average. Additionally, StemCells
Inc. has an RSI of 32.05. Register for free on Equity Research
Institute and access the latest research on STEM at:
https://www.EquityResearchInstitute.com/reports?keyword=STEM
On Thursday, shares in Northwest Biotherapeutics Inc. recorded a
trading volume of 0.73 million shares, higher than their three
months average volume of 0.60 million shares. The stock ended the
day 1.83% higher at $12.24. Northwest
Biotherapeutics Inc.'s stock has surged 19.18% in the last one
month, 42.00% in the previous three months and 128.79% on YTD
basis. The company is trading above its 50-day and 200-day moving
averages by 25.99% and 70.06%, respectively. Furthermore, shares of
Northwest Biotherapeutics Inc. have an RSI of 78.69. The complete
research on NWBO is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=NWBO
Acorda Therapeutics Inc.'s stock lost 1.36%, to close Thursday's
session at $34.75. The stock recorded
a trading volume of 0.26 million shares, below its three months
average volume of 0.60 million shares. Over the last one month and
since the start of this year, Acorda Therapeutics Inc.'s shares
have fallen by 0.34% and 14.97%, respectively. However, the stock
has gained 3.73% in the previous three months. The company is
trading 6.83% above its 50-day moving average. Furthermore, Acorda
Therapeutics Inc.'s stock traded at a PE ratio of 105.30 and has an
RSI of 55.70. Free in-depth research on ACOR is available at:
https://www.EquityResearchInstitute.com/reports?keyword=ACOR
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com